Led · Series B · Jul 2026

Neusignal Therapeutics is developing NTX-083, a novel low-molecule compound intended to treat Alzheimer’s disease via a mechanism distinct from existing therapies. The company completed a physician-initiated single-dose Phase 1 trial at the University of Tokyo Hospital (Feb–Sep 2025) and a company-sponsored multiple-dose Phase 1 trial (Nov 2025–Mar 2026) in healthy adults, with both Japanese trials reporting high safety, strong tolerability, and favorable pharmacokinetics and no significant side effects. Neusignal plans to begin a Phase 1b trial in Alzheimer’s patients in the United States later this year. The company intends to use the Series B proceeds to fund that U.S. trial and to expand its workforce ahead of potential strategic alliances with global pharmaceutical firms. Neusignal originated from Tohoku University and is headquartered in Tokyo.

Led · Series A · Jun 2026

Founded in 2022 and based in Tokyo, M2X develops a cloud-based all-in-one system for maintenance operations and AI-powered preventive maintenance. The company serves clients across 40 industries and counts major manufacturers such as Toyota Motor Kyushu, Lotte and Rengo among its customers. Since its previous funding round, M2X has reported 700% revenue growth. M2X articulates a "Zero Downtime Vision" aimed at preventing machinery failures. The recent funding is earmarked to strengthen hiring in both business and product teams as the company scales. These moves are positioned to expand M2X's deployment of its maintenance platform across industrial customers.

Participated · Series A · Jun 2026

GenerativeX is headquartered in Chiyoda-ku, Tokyo and is led by CEO Rei Araki. The company announced a Series A round raising approximately ¥650 million through a third-party allotment. The round was led by Nissay Capital with participation from Salesforce Ventures, Angel Bridge, Deepcore and SMBC Venture Capital. The company’s announcement did not disclose a valuation or prior funding history. The article did not provide details on the company’s products, operations, or financial metrics. The filing likewise did not specify intended use of the newly raised capital.

Led · Series C · May 2026

Henry provides a cloud-based integrated electronic medical record, ordering, and billing system designed as a cloud-native alternative to traditional on-premise hospital systems. Since launching for hospitals in February 2023, the company reports customer outcomes including increases in bed occupancy from 60% to 100%, revenue uplifts of up to 30%, and reductions in staff overtime of 70–80%, with at least one Osaka hospital exempting doctors from night shifts. Henry plans to add AI features such as voice input, automated workflow generation, and AI-driven billing agents, and to expand value-added services and BPO offerings for facility, clerical, and nursing operations. Financially, Henry has raised approximately ¥5.7 billion to date, including the ¥3 billion Series C, following a ¥730 million Series A and a ¥1 billion Series B. The company was founded in May 2018 and is led by CEO Akito Sakasegawa.

Led · Series A · Apr 2026

Ricerca develops RECERQA, described as an Agentic ERP that optimizes order placement and processing through autonomous data normalization and AI-driven decision support. The system uses a four-tier architecture called "Quattro" to normalize operational data and leverage accumulated data to support business decision-making and execution. Ricerca says that as more operational data is collected post-implementation, the AI's decision accuracy improves and the need for human verification declines. The company recently revamped its system to emphasize Agentic ERP characteristics distinct from conventional ERPs. Ricerca plans to expand its commercial rollout to major manufacturing and trading companies while scaling its team, prioritizing hires of AI engineers and forward-deployed engineers (FDEs). Financially, the company has raised ¥1.7 billion in Series A funding, with total financing exceeding ¥2 billion to date.